Court throws out Merck Sharp & Dohme’s Januvia patent extension

Intellectual Property 2021-08-12 2:29 pm | Sydney
The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.
For information on rights and reprints, contact subscriptions@lawyerly.com.au